Entry time effects and follow-on drug competition
Author
Abstract
Suggested Citation
DOI: 10.1007/s10198-014-0654-9
Download full text from publisher
As the access to this document is restricted, you may want to look for a different version below or search for a different version of it.
Other versions of this item:
- Luiz Flavio Andrade, 2011. "Entry time effects and follow on drug competition," Post-Print halshs-00658247, HAL.
- Luiz Flavio Andrade, 2012. "Entry Time Effects and Follow-on Drugs Competition," Working Papers DT49, IRDES institut for research and information in health economics, revised Jun 2012.
- Luiz Flavio Andrade & Catherine Sermet & Sylvain Pichetti, 2016. "Entry time effects and follow-on drug competition," Post-Print halshs-01156509, HAL.
References listed on IDEAS
- Luc Behaghel & Didier Blanchet & Thierry Debrand & Muriel Roger, 2012.
"Disability and Social Security Reforms: The French Case,"
NBER Chapters, in: Social Security Programs and Retirement around the World: Historical Trends in Mortality and Health, Employment, and Disability Insurance Participatio, pages 301-326,
National Bureau of Economic Research, Inc.
- Luc Behaghel & Didier Blanchet & Thierry Debrand & Muriel Roger, 2011. "Disability and social security reforms: The French case," Working Papers halshs-00556722, HAL.
- Luc Behaghel & Didier Blanchet & Thierry Debrand & Muriel Roger, 2011. "Disability and social security reforms: The French case," PSE Working Papers halshs-00556722, HAL.
- Luc Behaghel & Didier Blanchet & Thierry Debrand & Muriel Roger, 2011. "Disability and Social Security Reforms:The French Case," Working Papers DT38, IRDES institut for research and information in health economics, revised Feb 2011.
- Luc Behaghel & Blanchet Didier & Debrand Thierry & Muriel Roger, 2012. "Disability and Social Security Reforms: The French Case," Post-Print hal-01504234, HAL.
- Luc Behaghel & Didier Blanchet & Thierry Debrand & Muriel Roger, 2011. "Disability and Social Security Reforms: The French Case," NBER Working Papers 17055, National Bureau of Economic Research, Inc.
- Luc Behaghel & Blanchet Didier & Debrand Thierry & Muriel Roger, 2012. "Disability and Social Security Reforms: The French Case," PSE-Ecole d'économie de Paris (Postprint) hal-01504234, HAL.
- de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges, 2013.
"Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 268-285.
- Siotis, Georges & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2010. "Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?," CEPR Discussion Papers 8076, C.E.P.R. Discussion Papers.
- Grabowski, Henry, 2002. "Patents, Innovation and Access to New Pharmaceuticals," Working Papers 02-28, Duke University, Department of Economics.
- Ilaria Mosca & Marc Pomp & Victoria Shestalova, 2010. "Market Share and Price in Dutch Home Care: Market Power or Quality?," De Economist, Springer, vol. 158(1), pages 61-79, April.
- Glenn Ellison & Sara Fisher Ellison, 2011.
"Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration,"
American Economic Journal: Microeconomics, American Economic Association, vol. 3(1), pages 1-36, February.
- Glenn Ellison & Sara Fisher Ellison, 2007. "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration," NBER Working Papers 13069, National Bureau of Economic Research, Inc.
- Hannah Kettler, 1998. "Competition through Innovation, Innovation through Competition," Monograph 000434, Office of Health Economics.
- Henry Grabowski, 2002. "Patents, Innovation and Access to New Pharmaceuticals," Journal of International Economic Law, Oxford University Press, vol. 5(4), pages 849-860, December.
- Gregory S. Crawford & Matthew Shum, 2005. "Uncertainty and Learning in Pharmaceutical Demand," Econometrica, Econometric Society, vol. 73(4), pages 1137-1173, July.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
- Christine Sorasith & Sylvain Pichetti & Thomas Cartier & Laure Bergua & Catherine Sermet, 2012. "Déterminants de l’écart de prix entre médicaments similaires et le premier entrant d’une classe thérapeutique," Working Papers DT43, IRDES institut for research and information in health economics, revised Feb 2012.
- Coscelli, Andrea & Shum, Matthew, 2004. "An empirical model of learning and patient spillovers in new drug entry," Journal of Econometrics, Elsevier, vol. 122(2), pages 213-246, October.
- Aidan Hollis, 2002. "The importance of being first: evidence from Canadian generic pharmaceuticals," Health Economics, John Wiley & Sons, Ltd., vol. 11(8), pages 723-734, December.
- Regan, Tracy L., 2008.
"Generic entry, price competition, and market segmentation in the prescription drug market,"
International Journal of Industrial Organization, Elsevier, vol. 26(4), pages 930-948, July.
- Tracy L. Regan, 2007. "Generic entry, price competition, and market segmentation in the prescription drug market," Working Papers 2010-7, University of Miami, Department of Economics.
- Harris, Christopher J & Vickers, John S, 1985. "Patent Races and the Persistence of Monopoly," Journal of Industrial Economics, Wiley Blackwell, vol. 33(4), pages 461-481, June.
- Hall, Robert E, 1988.
"The Relation between Price and Marginal Cost in U.S. Industry,"
Journal of Political Economy, University of Chicago Press, vol. 96(5), pages 921-947, October.
- Robert E. Hall, 1986. "The Relation Between Price and Marginal Cost in U.S. Industry," NBER Working Papers 1785, National Bureau of Economic Research, Inc.
- Edwin Mansfield, 1986. "Patents and Innovation: An Empirical Study," Management Science, INFORMS, vol. 32(2), pages 173-181, February.
- Peter W Roberts, 2001. "Innovation and firm-level persistent profitability: a Schumpeterian framework," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 22(4-5), pages 239-250.
- Catherine M. Banbury & Will Mitchell, 1995. "The effect of introducing important incremental innovations on market share and business survival," Strategic Management Journal, Wiley Blackwell, vol. 16(S1), pages 161-182.
- John R. Virts & J. Fred Weston, 1980. "Returns to research and development in the us pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 1(3), pages 103-111, September.
- Deeds, David L. & Hill, Charles W. L., 1996. "Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms," Journal of Business Venturing, Elsevier, vol. 11(1), pages 41-55, January.
- Lundin, Douglas, 2000. "Moral hazard in physician prescription behavior," Journal of Health Economics, Elsevier, vol. 19(5), pages 639-662, September.
- Agarwal, Rajshree & Gort, Michael, 2001. "First-Mover Advantage and the Speed of Competitive Entry, 1887-1986," Journal of Law and Economics, University of Chicago Press, vol. 44(1), pages 161-177, April.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Ana Beatriz D′Avó Luís & Mikyung Kelly Seo, 2021. "Has the development of cancer biomarkers to guide treatment improved health outcomes?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 789-810, July.
- Mohamed Ali Ben Halima & Thierry Debrand & Camille Regaert, 2012. "Sick Leaves: Understanding Disparities Between French Departments," Working Papers DT50, IRDES institut for research and information in health economics, revised Oct 2012.
- Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021.
"Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions,"
Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
- Farasat A.S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2019. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2016-01v3, Centre for Competition Policy, University of East Anglia, Norwich, UK..
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
- Aljoscha Janssen, 2022. "Price dynamics of Swedish pharmaceuticals," Quantitative Marketing and Economics (QME), Springer, vol. 20(4), pages 313-351, December.
- Skipper, Niels & Vejlin, Rune, 2015.
"Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data,"
Social Science & Medicine, Elsevier, vol. 130(C), pages 204-215.
- Niels Skipper & Rune Vejlin, 2013. "Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data," Economics Working Papers 2013-05, Department of Economics and Business Economics, Aarhus University.
- Thomas Lebesmuehlbacher & Rhet A. Smith, 2021. "The effect of medical cannabis laws on pharmaceutical marketing to physicians," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2409-2436, September.
- Dalen, Dag Morten & Sorisio, Enrico & Strøm, Steinar, 2009.
"Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?,"
Memorandum
10/2009, Oslo University, Department of Economics.
- Dag Morten Dalen & Enrico Sorisio & Steinar Strøm, 2010. "Choosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?," CESifo Working Paper Series 3227, CESifo.
- Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
- Janssen, Aljoscha, 2020. "Price Dynamics of Swedish Pharmaceuticals," Working Paper Series 1325, Research Institute of Industrial Economics.
- Andrew J. Epstein & Jonathan D. Ketcham, 2014. "Information technology and agency in physicians' prescribing decisions," RAND Journal of Economics, RAND Corporation, vol. 45(2), pages 422-448, June.
- Hoffman, Mitchell & Burks, Stephen V., 2017.
"Worker Overconfidence: Field Evidence and Implications for Employee Turnover and Returns from Training,"
IZA Discussion Papers
10794, Institute of Labor Economics (IZA).
- Mitchell Hoffman & Stephen V. Burks, 2017. "Worker Overconfidence: Field Evidence and Implications for Employee Turnover and Returns from Training," NBER Working Papers 23240, National Bureau of Economic Research, Inc.
- Dolfsma, W.A., 2006. "IPRs, Technological Development, and Economic Development," ERIM Report Series Research in Management ERS-2006-004-ORG, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
- Jie Bai, 2016. "Melons as Lemons: Asymmetric Information, Consumer Learning and Seller Reputation," Natural Field Experiments 00540, The Field Experiments Website.
- Kohei Kawaguchi, 2021. "When Will Workers Follow an Algorithm? A Field Experiment with a Retail Business," Management Science, INFORMS, vol. 67(3), pages 1670-1695, March.
- Castanheira, Micael & Ornaghi, Carmine & Siotis, Georges, 2019.
"The unexpected consequences of generic entry,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Micael Castanheira De Moura & Carmine Ornaghi & Georges Siotis, 2019. "The Unexpected Consequences of Generic Entry," Working Papers ECARES 2019-21, ULB -- Universite Libre de Bruxelles.
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2019. "The Unexpected Consequences of Generic Entry," ULB Institutional Repository 2013/298643, ULB -- Universite Libre de Bruxelles.
- Balat, Jorge & Papageorge, Nicholas W. & Qayyum, Shaiza, 2017.
"Positively Aware? Conflicting Expert Reviews and Demand for Medical Treatment,"
IZA Discussion Papers
10919, Institute of Labor Economics (IZA).
- Jorge F. Balat & Nicholas W. Papageorge & Shaiza Qayyum, 2018. "Positively Aware? Conflicting Expert Reviews and Demand for Medical Treatment," NBER Working Papers 24820, National Bureau of Economic Research, Inc.
- Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011.
"Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008,"
CESifo Working Paper Series
3441, CESifo.
- Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
- Paraponaris, A. & Verger, P. & Desquins, B. & Villani, P. & Bouvenot, G. & Rochaix, L. & Gourheux, J. C. & Moatti, J. P. AU -, 2004. "Delivering generics without regulatory incentives?: Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names," Health Policy, Elsevier, vol. 70(1), pages 23-32, October.
- Ivan Moreno-Torres, 2011. "Generic drugs in Spain: price competition vs. moral hazard," Working Papers XREAP2011-04, Xarxa de Referència en Economia Aplicada (XREAP), revised May 2011.
- Granlund, David & Sundström, David, 2018. "Physicians prescribing originals causes welfare losses," Economics Letters, Elsevier, vol. 170(C), pages 143-146.
More about this item
Keywords
Incremental innovation; Follow-on drugs; Entry timing; Market share; I11; I18; C5; L65;All these keywords.
JEL classification:
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I12 - Health, Education, and Welfare - - Health - - - Health Behavior
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
- L51 - Industrial Organization - - Regulation and Industrial Policy - - - Economics of Regulation
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:17:y:2016:i:1:p:45-60. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.